GSK Stock Dips Amid Mixed EU Respiratory Drug Approvals
GSK shares declined as European regulators delivered a split verdict on the company's respiratory drug portfolio. While the EMA's CHMP recommended approvals for Nucala and Arexvy, the lack of final decisions created uncertainty that overshadowed near-term growth prospects.
All eyes now turn to the FDA's December 16 decision on depemokimab, which could reshape market sentiment. The asthma treatment's potential approval represents the most immediate catalyst for the pharmaceutical giant's stock performance.
Analysts note the 1.5% drop in London trading reflects cautious positioning rather than structural concerns. Buyback programs and dividend reinvestment offer limited support as investors await clearer regulatory pathways for GSK's respiratory franchise.
